Clinical Profile and Outcomes of Pulmonary Embolism in Central Iran: A Retrospective Cohort Study

Overview

Journal Arch Iran Med

Date 2025 Feb 1

PMID 39891454

Authors

Abbas Andishmand

Leila Sharifi

Seyedeh Mahdieh Namayandeh

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary embolism (PE) is a significant public health concern. This retrospective cohort study examines the clinical profiles and outcomes of patients diagnosed with PE at a medical center in central Iran, aiming to identify mortality predictors during hospitalization and follow-up.

Methods: Data from 109 patients diagnosed with PE were analyzed, with a median follow-up of 23 months. The collected information included demographic and clinical characteristics, laboratory findings, treatment protocols, and outcomes. Logistic regression and Kaplan-Meier survival analysis were used to identify independent mortality predictors and assess survival impact.

Results: The mean age was 59.2 years (±19.7), with 51.4% male. Common symptoms included dyspnea (86%) and chest pain (53%), with non-massive PE being the most prevalent (63%). Independent mortality predictors identified were age (odds ratio [OR] 1.065 per year, <0.001), female sex (OR 4.421, =0.009), and PE severity (OR 0.262, =0.023). Kaplan-Meier analysis showed reduced survival probabilities in females (=0.009), those with provoked PE (=0.002), patients over 65 (=0.016), and individuals with comorbidities (=0.018). In-hospital mortality was 10.1%, linked to provoked massive PE, absence of thrombolytic therapy, and reduced left ventricular ejection fraction (LVEF).

Conclusion: In this cohort, age, sex, and PE severity were significant mortality predictors, while provoked PE, advanced age, and comorbidities were associated with lower mid-term survival probabilities.

References

Minges K, Bikdeli B, Wang Y, Kim N, Curtis J, Desai M . National Trends in Pulmonary Embolism Hospitalization Rates and Outcomes for Adults Aged ≥65 Years in the United States (1999 to 2010). Am J Cardiol. 2015; 116(9):1436-42. PMC: 4841688. DOI: 10.1016/j.amjcard.2015.07.068. View

Nasser M, Jabri A, Limaye S, Sharma S, Hamade H, Mhanna M . Echocardiographic Evaluation of Pulmonary Embolism: A Review. J Am Soc Echocardiogr. 2023; 36(9):906-912. DOI: 10.1016/j.echo.2023.05.006. View

Rivera-Lebron B, McDaniel M, Ahrar K, Alrifai A, Dudzinski D, Fanola C . Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. Clin Appl Thromb Hemost. 2019; 25:1076029619853037. PMC: 6714903. DOI: 10.1177/1076029619853037. View

Eckelt J, Hobohm L, Merten M, Pagel C, Eggers A, Lerchbaumer M . Long-term mortality in patients with pulmonary embolism: results in a single-center registry. Res Pract Thromb Haemost. 2023; 7(5):100280. PMC: 10439384. DOI: 10.1016/j.rpth.2023.100280. View

Sekhri V, Mehta N, Rawat N, Lehrman S, Aronow W . Management of massive and nonmassive pulmonary embolism. Arch Med Sci. 2013; 8(6):957-69. PMC: 3542486. DOI: 10.5114/aoms.2012.32402. View

Yang J, Madani M, Mahmud E, Kim N . Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension. Chest. 2023; 164(2):490-502. PMC: 10410247. DOI: 10.1016/j.chest.2023.03.029. View

Hsu S, Ko C, Chou E, Herrala J, Lu T, Wang C . Pulmonary embolism in United States emergency departments, 2010-2018. Sci Rep. 2023; 13(1):9070. PMC: 10241783. DOI: 10.1038/s41598-023-36123-2. View

Panahi L, Udeani G, Horseman M, Weston J, Samuel N, Joseph M . Review of Medical Therapies for the Management of Pulmonary Embolism. Medicina (Kaunas). 2021; 57(2). PMC: 7912594. DOI: 10.3390/medicina57020110. View

Tarbox A, Swaroop M . Pulmonary embolism. Int J Crit Illn Inj Sci. 2013; 3(1):69-72. PMC: 3665123. DOI: 10.4103/2229-5151.109427. View

10.

Bejjani A, Khairani C, Campia U, Piazza G . Pulmonary Embolism Response Teams: Theory, Implementation, and Unanswered Questions. J Clin Med. 2022; 11(20). PMC: 9605063. DOI: 10.3390/jcm11206129. View

11.

Munoz-Torrero J, Bounameaux H, Pedrajas J, Lorenzo A, Rubio S, Kearon C . Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. J Vasc Surg. 2011; 54(6 Suppl):26S-32S. DOI: 10.1016/j.jvs.2011.05.114. View

12.

Levis J . ECG Diagnosis: Pulmonary Embolism. Perm J. 2012; 15(4):75. PMC: 3267566. DOI: 10.7812/tpp/11-112. View

13.

Shoeb M, Fang M . Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013; 35(3):312-9. PMC: 3888359. DOI: 10.1007/s11239-013-0899-7. View

14.

Couturaud F . [The optimal duration of anticoagulant treatment following pulmonary embolism]. Rev Mal Respir. 2011; 28(10):1265-77. DOI: 10.1016/j.rmr.2011.04.017. View

15.

Belohlavek J, Dytrych V, Linhart A . Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013; 18(2):129-38. PMC: 3718593. View

16.

Duffett L, Castellucci L, Forgie M . Pulmonary embolism: update on management and controversies. BMJ. 2020; 370:m2177. DOI: 10.1136/bmj.m2177. View

17.

Jin J . JAMA PATIENT PAGE. Treatment Duration for Pulmonary Embolism. JAMA. 2015; 314(1):98. DOI: 10.1001/jama.2015.7431. View

18.

Hojen A, Nielsen P, Overvad T, Albertsen I, Klok F, Rolving N . Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation. J Clin Med. 2022; 11(19). PMC: 9571065. DOI: 10.3390/jcm11195970. View

19.

Ng A, Chung T, Yong A, Wong H, Chow V, Celermajer D . Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes. 2010; 4(1):122-8. DOI: 10.1161/CIRCOUTCOMES.110.958397. View

20.

Rosovsky R, Zhao K, Sista A, Rivera-Lebron B, Kabrhel C . Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. Res Pract Thromb Haemost. 2019; 3(3):315-330. PMC: 6611377. DOI: 10.1002/rth2.12216. View